Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial (Wellcome Open Research, 2023)

(untitled) - Hamaluba, M; Sang, S; Orindi, B; Njau, I; Karanja, H; Kamau, N; Gitonga, J; Mugo, D; Wright, D; Nyagwange, J; Kutima, B; Omuoyo, D; et al.